论文部分内容阅读
目的探讨莫沙必利联合舒肝解郁胶囊治疗功能性消化不良患者的临床疗效。方法选取2015年1月至2016年1月辽宁省盘锦市中医医院收治的92例功能性消化不良患者作为研究对象,按随机数字表法将其分为对照组与观察组,各46例。对照组患者餐前30 min服用莫沙必利,观察组患者在对照组用药基础上采用疏肝解郁胶囊进行治疗,比较两组患者症状改善情况、治疗效果及用药安全性,随访6个月,统计其复发率。结果治疗后,观察组患者上腹胀痛、餐后饱胀、嗳气、食欲下降评分均明显低于对照组,差异均有统计学意义(均P<0.05);观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);随访6个月,观察组患者的复发率明显低于对照组,差异有统计学意义(χ~2=10.7257,P=0.0010)。结论对功能性消化不良患者采取莫沙必利联合疏肝解郁胶囊治疗的疗效显著,可有效改善患者的临床症状,且安全性较高,复发率低。
Objective To investigate the clinical efficacy of mosapride combined with Shugan Jieyu capsule in patients with functional dyspepsia. Methods Ninety-two patients with functional dyspepsia admitted from Panjin Chinese Medicine Hospital of Liaoning Province from January 2015 to January 2016 were selected as study subjects, and randomly divided into control group and observation group according to random number table method, with 46 cases in each group. Patients in the control group took Mosapride 30 min before meals. The patients in the observation group were treated with Shugan Jieyu capsules on the basis of the control group. The improvement of symptoms, treatment and medication safety were compared between the two groups. The patients were followed up for 6 months , Statistics of the recurrence rate. Results After treatment, the patients in the observation group had significantly lower abdominal pain, postprandial fullness, belching and appetite reduction than those in the control group (all P <0.05). The total effective rate (P <0.05). The follow-up of 6 months showed that the recurrence rate of the observation group was significantly lower than that of the control group (χ ~ 2 = 10.7257, P = 0.0010), and the difference was statistically significant . Conclusion The treatment of functional dyspepsia patients with Mosapride combined with Shugan Jieyu capsule significantly improved the clinical symptoms of patients with high safety and low recurrence rate.